Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Recce Pharmaceuticals
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
27 févr. 2025 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it...
Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
19 févr. 2025 08h00 HE
|
Recce Pharmaceuticals
Phase II trial assessed the efficacy and safety of RECCE® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections...
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
22 janv. 2025 08h00 HE
|
Recce Pharmaceuticals
Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data analysis expected in Q1 2025Additional...
Recce Pharmaceuticals Receives Approval from Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections
10 déc. 2024 08h00 HE
|
Recce Pharmaceuticals
Registrational Phase 3 trial for diabetic foot infections to be conducted across Indonesia, one of the world's largest diabetes patient populationsAwarded expedited regulatory review status in...
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives
27 nov. 2024 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, today announced the Australian Patent Office...
Recce Pharmaceuticals Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections
12 nov. 2024 08h00 HE
|
Recce Pharmaceuticals
Human Research Ethics Committee approval received for registrational Phase 3 trial for RECCE® 327 topical gel in patients with diabetic foot infectionsRegistrational Phase 3 clinical trial for...
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections
06 nov. 2024 08h00 HE
|
Recce Pharmaceuticals
Trial reaches dosing milestone, with 20 of the 30 total patients dosedAll patients dosed met the primary endpoints of the study, either a cure or notable improvement following treatment with RECCE®...
Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial
31 oct. 2024 08h00 HE
|
Recce Pharmaceuticals
RECCE® 327 Topical Gel (R327G) was demonstrated to be safe and well-tolerated in patients – R327G demonstrating highly encouraging efficacy results as determined by non-Data Safety Monitoring BoardAll...
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections
10 oct. 2024 08h00 HE
|
Recce Pharmaceuticals
Phase II trial assessing the efficacy of RECCE® 327 topical gel (R327G) against acute bacterial skin and skin structure infectionsR327G demonstrating promising antibacterial effect across a broad...
Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
06 août 2024 08h00 HE
|
Recce Pharmaceuticals
A$4.4 million of valid applications received for the Share Purchase PlanIn conjunction with recently completed A$8.0 million institutional placement, total amount raised is A$12.4 millionProceeds will...